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Interleukin-1-induced IL-8 and IL-6 gene expression and
production in human mesangial cells is differentially regulated
by cAMP
RACHEL L. ROBSON, JOHN WESTWICK, and ZARIN BROWN
Department of Phannacology, University of Bath, Claverton Down, Bath, Avon, England, United Kingdom
Interleukin-1-induced IL-8 and IL-6 gene expression and production in
human mesangial cells is differentially regulated by cAMP. We have
previously proposed that activated mesangial cells (MC) have a direct role
in the initiation and propagation of inflammatory events within the
glomerulus via the generation of the mesangioproliferative cytokine IL-6
and the chemokines IL-8 and MCP-1. The objective of this study was to
investigate the role of cAMP in the regulation of IL-6 and IL-8 gene
expression and peptide production in IL-I stimulated human MC. Agents
known to elevate cAMP, including dibutyryl cAMP (db-cAMP), forskolin
or isobutyl-methybcanthine (IBMX) were alone unable to induce IL-6 or
IL-8 expression or production above media control levels, indicating
activation of the cAMP pathway could not mimic IL-i signaling events. In
the presence of IL-i, all three agents produced a marked potentiation of
IL-6 mRNA expression and dose-dependent increase in IL-6 peptide
production (twofold), but had little or no effect on IL-8 mRNA expression
or peptide generation. In marked contrast cholera toxin (CT) caused a
dose-dependent potentiation of both IL-I-induced IL-6 (." fourfold) and
IL-8 peptide (" twofold) generation. The control agent, the purified
binding subunit of cholera toxin (CT-B) which is devoid of ADP-
ribosylating activity also enhanced IL-6 and IL-8 ( twofold) peptide
generation indicating cAMP-independent mechanisms may be involved in
the CT up-regulation of these cytokines. Treatment of MC with the
cycloxygenase inhibitor indomethacin resulted in partial inhibition (37%)
of IL-6 production but had no effect on IL-8 generation. Thus our data
show that cAMP can potentiate IL-i induced IL-6 production, while
having no effect on IL-8 induction, and PGE2 may operate via a positive
feedback loop to up-regulate IL-i induced IL-6. Taken together, our
results demonstrate that cAMP differentially regulates IL-6 and TL-8
production in IL-I-stimulated human MC.
Mesangial cells (MC) are mesenchymally-derived smooth mus-
cle cells that fulfill the function of specialized pericytes within the
glomerulus of the kidney. MC regulate a number of important
functions including glomerular filtration rate (GFR) and matrix
synthesis, as well as providing support for the capillary loops [1].
Increasing evidence from both in vitro and in vivo studies impli-
cates mesangial cells, once considered a non-immune bystander
cell, to participate in the initiation and maintenance of inflamma-
tory events within the glomerulus, such as glomerulonephritis [2].
Mesangial cells can serve as both a source and target for numer-
ous cytokines, eicosanoids and reactive oxygen intermediates [2,
3]. For example, we have demonstrated that human MC are a rich
source of the neutrophil chemotactic peptide, IL-8, monocyte
chemoattractant protein I (MCP-1) as well as the mesangiopro-
liferative cytokine IL-6 when activated by the pro-inflammatory
cytokines IL-i and TNF [4—61.
The signaling mechanisms employed by IL-i to activate cells
remain to be fully defined. IL-i induces a rapid change in the
phosphorylation pattern of a large number of proteins chiefly on
serine and threonine residues indicating activation of kinases or
inhibition of phosphatases specific for these target residues [7—9].
The kinases involved remain to be identified, but are thought to
be novel since IL-i-induced phosphorylation events have been
shown to be largely independent of cAMP-dependent protein
kinase and protein kinase C activation [7, 101. Furthermore, there
is no consensus on whether IL-I generates cAMP or diacylglyc-
erol, as some investigators have found changes in these second
messengers and others have not [11, 12]. While the role of cAMP
in IL-i signaling events remain controversial, addition of cAMP
elevating agents to immunologically-stimulated cells can have
important regulatory effects on cytokine production. For example,
elevation of cAMP down-regulates IL-6 production by IL-i
stimulated lung fibroblasts [13], MCP-1 production by TNF
stimulated mouse MC [14] and TNF production by endotoxin
stimulated monocytes [15].
Little is known about the regulatory effects of cAMP on
cytokine production in mesangial cells. This study was designed,
therefore, to examine the role of cAMP in the regulation of IL-6
and IL-8 gene expression and protein production in IL-I stimu-
lated human MC. The effects of cAMP on IL-6 and IL-8 produc-
tion were determined pharmacologically by utilizing agents which
elevate cAMP, including dibutyryl cAMP (db-cAMP), forskolin
and 3-isobutyl-1-methyl-xanthine (IBMX) or cholera toxin (CT),
an agent which elevates cAMP via activation and ribosylation of
the guannine nucleotide binding protein G (stimulatory protein)
[16]. Our data demonstrates that cAMP differentially regulates
IL-6 and IL-8 production in IL-i stimulated human MC.
Methods
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Materials
Recombinant human IL-la (specific activity 3 X 108 U/mg) was
a gift from Hoffman La Roche (Nutley, NJ, USA). Anti-human
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Fig. 2. Effect of the B oligomer on IL-la-induced IL-6 and IL-8 peptide
production. MC were pretreated with CT-B (10 to 250 ng/nil) for five hours
prior to stimulation with IL-icr (3 nglml) for 18 hours. Supernatants were
quantitated for extracellular IL-6 (A) and IL-8 (B) peptide by ELISA.
Results are expressed as a % of the IL-la control and are the mean SEM
of 4 separate experiments on MC isolated from 4 donor kidneys.
Dr. S. Poole (National Institute of Biological Standards and
Control, South Mimms, UK). Cell culture reagents were from
Gibco Life Technologies (UK) and cell culture plastics were from
Nunc (Denmark). The Digoxigenin (DIG) labeled cocktails of
oligonucleotide probes to IL-8 and IL-6 were purchased from
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Fig. 1. Cholera toxin potentiates IL-la induced IL-6 and IL-8 peptide
production by MC. Cells were pretreated with CT (10 to 250 ng/mI) for five
hours prior to stimulation with IL-la (3 ng/ml), or treated with media
alone (C) for 18 hours. Antigenic IL-6 (A) and IL-8 (B) levels of culture
supernatants were determined by ELISA. Results are expressed as a % of
the IL-icr control, where cells were stimulated with IL-ia alone for 18
hours, and are the mean SEM of 5 separate experiments on MC isolated
from 5 donor kidneys.
IL-8 antibodies and human recombinant IL-8 were provided by
Dr. I. Lindley of Sandoz Forschungsinstitut (Vienna, Austria).
Antisera to human IL-6 and human recombinant IL-6 were from
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Fig. 3. G proteins modified by Cholera toxin or
B-subunit in MC membranes and time course of
activation of G5 as detected by reduction in ADP-
ribosylation. Flasks of confluent MC were
pretreated with media alone (lanes 1,2) or 100
ng/ml CT for 30 minutes (lane 3), two hours
(lane 4), or four hours (lane 5). Membranes
were then extracted and 60 .rg of membrane
protein re-exposed to 50 ig/ml of pre-activated
CT-B (lane 1) or CT (lanes 2 to 5) in the
5 presence of [32P] NAD for 15 minutes at 37°C.
Membrane protein was resolved in a 12.5%
SDS-polyacrylamide gel and autoradiographed.
In lanes 3 to 5, the degree of G ribosylation
that occurred on the initial exposure of intact
cells to CT is inversely related to the amount of
ribosylation observed on the autorad, which
occurred during the second exposure of the cell
membranes to CT in the presence of a [ 32P1-
NAD label. The relevant part of the autorad is
shown and is a representative experiment of 3
separate studies carried out on MC isolated
from 2 donor kidneys.
British Bio-Technology (Oxford, UK). All components for the
DIG nucleic acid detection system and the positively charged
nylon membrane were purchased from Boehringer Mannheim
(Germany). The prostaglandin E2 [12511 radioimmunoassay (RIA)
kit and [32P]NAD (800 Ci/mmol) were from Dupont-NEN
(Boston, MA, USA). Preparations of cholera toxin were obtained
from Gibco. Purified cholera toxin B subunit were obtained from
Gibco and Sigma Chemical Co. (Poole, UK). All other chemicals
were purchased from Sigma or Fisons (UK).
Mesangial cell isolation and culture conditions
Human mesangial cells (MC) were isolated from macroscopi-
cally normal portions of renal cortex, obtained from human
kidneys immediately after surgical nephrectomy for renal carci-
noma. Glomeruli were isolated by differential sieving and MC
obtained by collagenase treatment as previously described [4].
Cultures were grown on either 1% gelatin coated tissue culture
flasks or 24-multiwell tissue culture plates, in Waymouth medium
MB 75 2/1 supplemented with 15% (vol/vol) heat-inactivated FCS,
penicillin-streptomycin (10 U/mI and 10 pg/mI, respectively) and
fungizone (0.5 xg/ml). MC identity was confirmed by the display
of the characteristic hillock structures in culture [17] and by the
use of a series of cell markers, as described previously [4]. MC in
this study were used between passages 3 and 7.
Experimental protocol
Confluent MC were either grown in 24-multiwell tissue culture
plates (-- 5 X i0 cells/well) or in 25 cm2 flasks (-- 8 X io
cells/flask). Twenty-four hours prior to the start of the experiment
the cells were washed and cultured in serum-free medium to make
quiescent. The agents under investigation (CT, CT-B, db-cAMP,
forskolin, IBMX, indomethacin or vehicle) were added to dupli-
cate wells or to flasks of quiescent MC for the times and doses
specified in the Figure legends. A sub-maximal dose [4] of IL-la
was added to the wells, which were incubated for a further 18
hours, before supernatants were collected, centrifuged to remove
cellular debris and stored at —70°C until assayed for extracellular
IL-8, IL-6 or PGE2. Similarly IL-la (3 ng/ml) was added to the
flasks for five hours, before total cellular RNA was extracted for
Northern analysis. Cell viability was routinely assessed at the end
of the experiment by phase microscopy and by trypan blue
exclusion.
Enzyme-linked immunoadsorbent assay (ELISA) for quantitation
of IL-8
IL-8 in culture supernatants was quantitated using a double-
ligand sandwich ELISA method as previously described [4].
Immuno plates (Nunc) were coated with anti-human IL-8 mouse
monoclonal antibody and detected with anti-human IL-8 goat
polyclonal antibody conjugated to alkaline phosphatase. The
substrate p-nitrophenyl phosphate was dissolved in 10% dieth-
anolamine buffer, pH 9.8 to a final concentration of I mg/mI.
Absorbance was read at 405 nm in an ELISA plate reader. The
detection range of the assay was 200 to 2000 pg/mI.
ELISA for IL-6
Goat anti-human IL-6 antisera was affinity purified, and bioti-
nylated according to the method described by Taktak et a! [18].
IL-6 in culture supernatants was detected using a double-ligand
sandwich ELISA [18]. Detection was via the streptavidin-peroxi-
dase system, using 0.2 mg/ml of the substrate o-phenylenediamine
dihydrochioride (OPD) dissolved in 0.1 M citric acid-phosphate
buffer, pH 5.0. Absorbance was read at 492 nm and the detection
range was between 30 and 2000 pg/mI.
Prostaglandin E2 (PGE2) assay
PGE2 levels in culture supernatants were quantitated by radio-
immunoassay using an iodinated analogue of PGE2, according to
the manufacturers instructions (NEN Research products, Du-
pont). The detection range of the assay was 5 to 500 pg/ml.
Northern blot analysis
Total cellular RNA was extracted using 4 M guanidinium-
thiocyanate buffer and isolated using phenol-chloroform (1:1
vol/vol) as previously described by Strieter et al [19]. After alcohol
precipitation, RNA was quantitated by measuring absorbance at
260 nm and 10 pg per lane fractionated on a formaldehyde, 1%
agarose gel. RNA was ethidium-bromide stained to confirm
uniform loading. RNA was transferred overnight to positively
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Fig. 4. Effect of Db-cAMP or forskolin on IL-i a-induced IL-b and IL-S
peptide release by MC. Cells were pretreated with Db-cAMP (10 to 100 tLM)
or forskolin (1 to 30 pM) for five hours before stimulation with IL-la (3
nglml) for 18 hours. The vehicle control (Veh) was 0.03% dimethyl-
sulphoxide (DMSO), which corresponded to the percentage DM80
present in the top concentration of forskolin used. Antigenic IL-6 (A) and
IL-8 (B) levels in culture supematants were quantitated by ELISA.
Results are expressed as % of IL-la controls and are the mean SCM of
3 separate experiments carried out on MC isolated from 4 donor kidneys.
+ IL-lu
Fig. 5. Effect of IBMX on IL-i a induced IL-b and IL-S peptide generation.
MC were pretreated with IBMX (1 to 300 pM) for one hour prior to
stimulation with IL-la (3 ng/ml) for 18 hours. Extracellular IL-b (A) and
IL-8 (B) levels in supernatants were determined by ELISA. Results are
expressed as % of IL-la controls and are the mean SCM of 4 separate
experiments carried out on MC isolated from 3 donor kidneys.
charged nylon membrane by capillary action and fixed by baking
at 120°C for 20 minutes. Prehybridization and hybridization was
conducted at 42°C for one hour and overnight, respectively, in
(I)
A
18s —
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hybridization solution (5 X SSC, 0.1% N-lauroylsarcosine, 0.02%
SDS, 1% (wt/vol) Boehringer blocking reagent). Oligonucleotide
probes were diluted to 10 ng/ml in hybridization solution. Mem-
branes were washed and non-specific binding Sites blocked by
incubating the membrane for 30 minutes in 1% (wt/vol) Boehr-
inger blocking reagent. Bound probes were detected by anti-
digoxygenin antibody (1:10,000 dilution) coupled to alkaline
phosphatase. Visualization is achieved using the chemilumines-
cent substrate lumigen PPD. Blots were exposed to X-ray film
(Kodak Omat AR5) for approximately one to two hours at room
temperature. Blots were quantitated by laser densitometry.
Preparation of cell membranes for ADP-ribosylation assay
Confluent, quiescent MC (3 X 106 cells/80 cm2 flasks) were
treated with media alone or 100 nglml of cholera toxin for 30
minutes, two or four hours. Two flasks per time point were used.
Cell membranes were prepared as described previously by O'Neill
et al [20]. Briefly, cells were washed in phosphate-buffered saline
Fig. 6. Effect of agents on IL-Irs induced IL-6
mRNA expression. (A) Flasks of confluent MC
F— T were pretreated for five hours with media alone0 (C), 100 pM Db-cAMP (Db), 30 !.LM forskolin
+ + (Fsk), 0.03% DMSO vehicle (Veh), 100 ng/ml
CT or 100 ng/ml CT-B subunit, before the
addition of IL-ia (3 ng/ml) to the drug
containing media. (B) MC were pretreated with
media alone (C) or 300 JLM IBMX for one hour
before addition of IL-la. After a five hours IL-
in stimulation, total RNA was extracted and
northern analysis carried out. Autoradiographs
(1) were analyzed by densitometry and the
results plotted using the densitometry
absorbance units (ii). The ethidium bromide
stained gels showing the 18S and 28S ribosomal
RNA demonstrate equal loading (iii).
Representative blots from i of 4 separate
experiments are shown, which were carried out
on MC isolated from 4 donor kidneys.
(PBS), suspended in hypotonic buffer (10 mt Tris, 1 mM MgCl2,
pH 7.2) containing a mixture of protease inhibitors [10 jig/mI of
pepstatin A, of aprotinin and leupeptin and 1 mvt phenylmethyl-
sulphonyl fluoride (PMSF)], and mixed with 4 volumes of 0.25 M
sucrose. The membranes were homogenized by 50 strokes in a
"tight" Dounce pestle, before being centrifuged for five minutes
at 500 x g to remove nuclei and unbroken cells. A membrane
enriched fraction was obtained following centrifugation of the
supernatant at 25,000 X g for 30 minutes at 4°C. The resulting
membrane pellets were resuspended in I ml of PBS + 1 mrvi
PMSF and stored at —70°C until used in the ADP-ribosylation
assay. Membrane protein was measured by the Coomassie bril-
liant blue dye binding method [21], using IgG as standard.
ADP-nbosylation assay
Extracted membranes were exposed to CT or CT-B in the
presence of a 32[P]-NAD label and the level of ADP-ribosylation
0 — .D — . —a =
÷ + +
.o
a
1772 Robson et at: Differential regulation of IL-8 and IL-6 by cAMP
(i)
18s "'
B
Statistical analysis
Peptide values were log10 transformed and data groups ana-
lyzed by two-way analysis of variance. Data which was significantly
different at the P < 0.05 level was then compared using Dunnetts
t-test for comparison of multiple groups to the control.
Results
Effect of cholera toxin on IL-I cx induced IL-6 and IL-8 peptide
production by human mesangial cells
Pretreatment of MC with CT (10 to 250 nglml) for five hours
prior to the addition of IL-la resulted in a dose-dependent and
significant (P < 0.05) increase in IL-6 (Fig. 1A) and IL-8 (Fig. 1B)
production, compared to cells treated with IL-la alone. CT (250
nglml) enhanced IL-6 and IL-8 production by 297 56% and 106
24% (mean SCM), respectively, compared with IL-la control
[IL-I control values = 5.1 1.5 ng/ml for IL-6 and 15 7.0 nglml
for IL-8 production (mean SEM, N = 5)]. MC treated with CT
alone (250 ng/ml) for the duration of the experiment showed no
induction of IL-6 or JL-8 peptide above media control levels (Fig.
1 A, B).
To assess whether the mechanism of CT potentiation was
through activation of G5 by ADP-ribosylation and subsequent
elevation of cAMP, the effects of the purified binding subunit of
cholera toxin (CT-B) on IL-la induced IL-6 and IL-8 peptide
generation was investigated. CT-B can bind to the cell surface, but
cannot modify G5 to activate the cAMP pathway due to the
absence of A-subunit which is present in the whole toxin. Surpris-
+ ingly, pretreatment with CT-B resulted in enhanced IL-6 (Fig. 2A)
and IL-8 (Fig. 2B) peptide production of 144 27% and 88
21% (mean SCM), respectively, compared to IL-i control.
However, the potentiation of IL-Ia induced IL-6 production by
CT-B was not dose-dependent over the dose range used.
(iii)
28s .'uu"u
18s —
Fig. 6. Continued.
determined using a modification of the method previously de-
scribed [20]. Briefly, 60 j.tg of membrane protein was incubated
with 50 .tg/ml of pre-activated cholera toxin (incubated with 10
mM dithiothreitol for 20 mm at 30°C to release SI subunit) or
cholera toxin B-subunit (CT-B), in 150 m potassium phosphate
pH 7.5, 10 mM thymidine, 0.5 m ATP, 50 .LM GTP, 10 LM
[32P]NAD (50 to 100 pCi/mi), in a final volume of 100 pl. After
incubating for 15 minutes at 30°C, the reaction was stopped by the
addition of I ml of cold potassium phosphate buffer, the mem-
branes collected by centrifugation, resuspended in 30 pl of sample
buffer and proteins were separated by electrophoresis in a 12.5%
SDS-polyaciylamide gel (20 x 16 cm) overnight at a constant
current of 10 mA per gel [22]. The gel was Coomassie blue stained
to determine equal loading, before being dried and exposed to
X-ray film (Kodak X-Omat) for two days at —70°C with intensi-
fying screens.
Ability of cholera toxin and the B-subunit to ADP-ribosylate
mesangial cell membrane proteins
ADP-ribosylation studies were carried out to confirm that CT
was able to modify G proteins in MC within a five hour
incubation with intact cells, and to check the purified CT-B
preparation for contamination with A subunit. MC membranes
treated with CT contained radiolabeled proteins of 42 kD and 52
kD (Fig. 3, lane 2). These correspond to the molecular weights of
two known forms of G protein [23]. To determine the extent of
ADP-ribosylation, cells were treated for various times (0.5, 2, and
4 hr) with CT (100 ng/ml). Membranes were then prepared and a
second exposure of 15 minutes to CT in the presence of [32P]-
NAD was carried out. Any G5 ADP-ribosylated during the initial
incubation of the cells would not have been available for ADP-
ribosylation during the incubation of the isolated membranes with
the toxin and [32P]-NAD. The intensity of the labeling by [32P]
would therefore be inversely related to the amount ADP-ribo-
sylated during the incubation of the cells with the toxin. Figure 3
(lanes 4, 5) shows that after two hours contact with CT all of the
G5 protein was ADP-ribosylated. It was concluded that the
conditions in which the CT enhanced IL-6 and IL-8 production (5
hr preincubation) would have resulted in a near-total ADP-
ribosylation and activation of G. In contrast, treatment of MC
membranes with B-subunit instead of CT failed to generate the 42
kD and 52 kD bands (Fig. 3, lane 1), indicating no contamination
of the CT-B preparation with A-subunit was observed.
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Ability of other cAMP-elevating agents to modulate IL-la induced
IL-6 and IL-8 peptide production
To clarify the role of cAMP in potentiating IL-ia induced IL-6
and IL-8, we went on to investigate the effect of agents that act via
different mechanisms to elevate cAMP. Db-cAMP is a membrane
permeable, hydrolysis resistant cAMP analogue [24], while fors-
kolin activates the catalytic subunit of the adenylyl cyclase enzyme
to cause increases in intracellular cAMP levels [25]. IBMX is a
non-specific phosphodiesterase inhibitor which prevents the
breakdown of cAMP within the cell [26. Pretreatment of MC for
five hours with Db-cAMP (ito 100 .LM) or forskolin (ito 30 jiM)
resulted in a dose-dependent increase in IL-la induced IL-6
peptide compared with IL-ia control (Fig. 4A). Maximal poten-
tiation of IL-6 induced by either Db-cAMP (100 jiM) or forskolin
(30 jiM), was 103 10% and 118 10% (mean 5EM),
respectively, compared to IL-ia alone. Similarly, a dose-depen-
dent increase in IL-ia induced IL-6 was observed following a one
Fig. 7. Effect of agents on IL-Ia induced IL-8
gene expression. MC were pretreated for five
hours with media alone (C), 100 jiM Db-cAMP
(Db), 30 jiM forskolin (Fsk), 0.03% DMSO
vehicle (Veh), 100 ng/ml CT, 100 ng/ml CT-B
or for one hour with 300 jiM IBMX. IL-la (3
ng/ml) was then added to the drug-containing
media. Total cellular RNA was extracted five
hours after IL-la stimulation and northern
analysis carried out. (A) Autoradiographs were
analyzed by densitometry and the results
plotted using the densitometry absorbance units
(B). The ethidium bromide stained gels showing
the 18S and 28S ribosomal RNA demonstrate
equal loading (C). Representative blots from 1
of 4 separate experiments are shown, which
were carried out on MC isolated from 4 donor
kidneys.
hour IBMX pretreatment, 300 jiM of IBMX resulted in a 133
43% increase in IL-6 production (Fig. 5A). None of the cAMP-
elevating agents employed enhanced IL-la induced IL-6 produc-
tion to the same extent as cholera toxin. In marked contrast,
Db-cAMP, forskolin or IBMX in the presence of IL-la did not
modify IL-8 production (Figs. 4B and 5B). None of these agents
when added alone to the cells for the duration of the experiment
caused any induction of IL-6 or IL-8 peptide above media control
levels (Figs. 4 and 5).
Effect of agents on IL-la induced IL-6 and IL-8 mRNA
expression by mesangial cells
We next examined the effect of these agents on IL-6 and IL-8
gene expression. Figure 6A and B shows that pretreatment with
Db-cAMP (100 j.LM), forskolin (30 jiM), CT (100 ng/ml) or CT-B
(100 ng/ml) for five hours, or IBMX (300 jiM) for one hour
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Fig. 8. Effect of indomethacin on IL-la stimulated IL-6 and IL-8 peptide
generation and PGE2 production by MC. Cells were incubated with 0.1 to 10
jLM indomethacin for one hour prior to stimulation with IL-in (3 nglml)
for 18 hours. The vehicle control (Veh) consisted of 0.036% ethanol,
which corresponds to the percentage ethanol present in the top concen-
tration of indomethacin used. The concentration of POE2 in culture
supernatant was determined by RIA (A), while extracellular IL-6 (B) and
IL-8 (C) levels in supernatant were quantitated by ELISA. Results are
expressed as % of the IL-la control and are the mean SEM of at least
3 separate experiments carried out on MC isolated from 3 donor kidneys.
Effect of indomefhacin on IL-la induced IL-6 and IL-8
production
Cytokine-activated human MC in culture are known to synthe-
size prostaglandins, and in particular PGE2 production is signifi-
cantly increased above basal levels following IL-i stimulation 27].
MC respond to POE2 which upon receptor binding causes acti-
vation of G and elevation of intracellular cAMP 28]. To inves-
tigate whether POE2 plays a role in the IL-ia induction of IL-6,
we incubated the cells with the cyclooxygenase inhibitor, indo-
methacin (0.1 to 10 jIM) for one hour prior to stimulation with
IL-ia. Figure 8A shows that treatment with indomethacin re-
sulted in almost complete inhibition of IL-la-induced PGE2
production. Greater than 97% of PGE2 production was inhibited
at a concentration of 10 j.M indomethacin, while a 37 6% (mean
SEM) reduction in IL-6 production was observed at the same
concentration of indomethacin (Fig. 8B). In contrast, indometha-
cm treatment had no inhibitory effect on IL-la-induced IL-8
generation (Fig. 8C). The inhibitory effect of indomethacin on
PGE2 and IL-6 production was not due to a toxic effect of the drug
treatment, since cell viability as assessed by trypan blue exclusion
was 100%. These results indicate that induction of IL-6 produc-
tion in MC following IL-i stimulation may be potentiated by
synthesis of PGE2, probably acting via stimulation of adenylyl
cyclase.
Discussion
This study was undertaken to determine the role of cAMP in
the regulation of IL-i induced expression of IL-6 and IL-8 in MC.
Our results show that agents that elevate cAMP (db-cAMP,
forskolin and IBMX) significantly potentiated expression of IL-6
gene transcripts and peptide production in response to IL-in,
while having little or no effect on IL-8 gene expression and
peptide production.
o In marked contrast, the bacterial toxin CT was unique in that it
was found to cause significant enhancement of both IL-6 and IL-8
peptide generation in response to IL-in. CT produced a marked
enhancement of IL-6 transcripts, but caused only a minor, if any,
increase in IL-8 transcripts, indicating that enhanced IL-8 peptide
levels may result from post-transcriptional effects of CT. Our data
A
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enhanced IL-la-induced IL-6 mRNA levels, compared with cells
treated with IL-la alone.
In comparison, Figure 7 demonstrates that pretreatment with
IBMX (300 .tM) or CT-B (100 ng/ml) had no effect on IL-la
induced IL-8 mRNA levels compared with the IL-la control,
while pretreatment with either Db-cAMP (100 I.LM), forskolin (30
fLM) or CT (100 nglml) resulted in a small potentiation of IL-la
induced IL-8 mRNA transcripts.
None of the cAMP-elevating agents alone induced either IL-6
or IL-8 gene expression (Figs. 6 and 7).
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indicate that the effect observed with CT cannot solely be
attributed to the elevation of cAMP via G activation, since CT-B
treatment (devoid of ADP-ribosyl activity) of the cells also
resulted in significant potentiation of IL-I induced IL-6 and IL-8
peptide, suggesting that cAMP-independent mechanisms may be
involved. The flat dose-response of IL-6 up-regulation by CT-B
may reflect saturation. Since the molecular weight of CT-B (—59
kD) is less than twofold lower than the molecular weight of the
holotoxin (—86 kD) [291, similar amounts of CT-B are present in
corresponding doses of the two agents. This implies that the larger
fold increase observed in IL-6 production following holotoxin
pretreatment compared to CT-B pretreatment may be due to the
presence of A-subunit, and consequently suggests some involve-
ment of cAMP-dependent mechanisms in the CT up-regulation of
IL-6. In comparison, CT-B and holotoxin (at 250 nglml) induced
similar fold increases in IL-8 generation. The contrasting dose
effects of CT-B on IL-6 and IL-8 generation favors differential
regulation of these cytokines. CT-B is known to bind to a specific
cell surface receptor, the ganglioside GM1. Furthermore, binding
of CT-B to GM1 has been reported to modulate intracellular
calcium levels and growth in several cell types [30, 31]. In addition,
an ability of the CT-B/GM I pathway to modulate iL-2 expression
via cAMP-independent mechanisms has been previously de-
scribed [30, 321. Studies have also indicated that CT can interfere
with signaling pathways other than the cAMP pathway, an ability
which is dependent on the ADP-ribosylating activity of the toxin
[331. Such action by CT is thought to account for expression of JE,
the mouse monocyte chemokine in BALB/3T3 cells [34]. There-
fore, an ability of CT to modulate a number of different signaling
pathways may account for its potentiating effects on IL-i-induced
IL-8 generation and explain the large increases seen in IL-6
generation, which could not be mimicked fully by the other cAMP
agonists.
From the results of this study, certain insights into the IL-I
signaling mechanisms for IL-6 and IL-8 can be drawn. In our
system, the lack of induction of either IL-6 or IL-8 gene expres-
sion or production in the presence of cAMP-elevating agents
alone indicates an inability of cAMP to mimic the actions of IL-i.
The potentiating effect of cAMP on IL-6 production by IL-i,
however, does indicate that the IL-i signaling pathway for IL-6
and the cAMP pathway interact. The ability of agents that elevate
cAMP to potentiate IL-6 gene transcripts, as well as peptide
production indicates that this cross-talk between the pathways is
occurring at the level of gene expression. Whether cAMP is
working to increase IL-6 mRNA stability, or transcription itself
remains to be established. However, reports demonstrating an
ability of cAMP to cause induction of transcription factors that
are involved in IL-6 gene expression [35], as well as in IL-I
signaling [36, 37] lends to speculation that the potentiating effect
of cAMP may be occurring at the level of transcription factor
induction.
Studies in human FS-4 fibroblasts describe IL-6 mRNA expres-
sion on stimulation with cAMP-elevating agents alone [38]. Fur-
thermore, cAMP was found to activate IL-6 transcription by a
reporter gene assay in HeLa cells [31 and the murine monocytic
cell line PU5-1.8 [35]. This contrasts with our findings in human
MC. The inability of cAMP-elevating agents alone to cause any
induction of IL-6 mRNA or peptide could be linked to the fact
our experiments were undertaken on quiescent MC, depleted of
FCS for 24 hours before use. Serum itself is known to induce IL-6
expression [39], and the presence of serum immediately prior to
agonist stimulation can result in pronounced increases in cAMP
accumulation [40]. However, other studies undertaken on cells
which were not depleted of serum [131 or which were stimulated
in the presence of low serum concentrations [41] also report an
inability of cAMP-elevating agents to stimulate IL-6 expression.
This indicates that cell specific differences exist in IL-6 gene
regulation, which alone cannot be explained by differing culture
conditions.
The ability of cAMP to enhance IL-6 generation in the presence
of cytokines has been previously reported in a human astrocytoma
cell line [411 and rat IEC epithelial cells [42]. In contrast Zitnik,
Zheng and Elias [13] have shown cAMP to significantly inhibit
IL-io induced IL-6 mRNA and peptide in a human lung fibro-
blast cell line. Furthermore, cAMP-elevating agents have been
shown to down-regulate endotoxin induced IL-6 in Kupifer cells
[43] and to have no effect on IL-6 generation in endotoxin-
stimulated mononuclear cells [44]. The reasons for the variations
in the ability of cAMP to modulate IL-6 production are not clear,
and are likely to involve cell specific differences. In addition, these
findings may reflect an ability of factors such as the timing of
cAMP elevation in relation to agonist stimulation [45], the dose of
cAMP-elevating agent employed [46], the agonist used [47] and
the activation state of the cell [48] to affect the type of regulation
observed. Preliminary studies in our laboratory have shown that
addition of db-cAMP simultaneously with IL-i, or five hours after
IL-i stimulation (data not shown) resulted in a similar potentia-
tion of IL-i induced IL-6 peptide, as described with a five hour
pretreatment of the cells.
The inability of cAMP to modulate IL-i-stimulated IL-8 gen-
eration highlights differences between the regulation of IL-6 and
IL-8 in human MC, and indicates that the pathway(s) used by IL-i
to induce IL-8 is independent of the cAMP pathway. Reports in
the literature describing an ability of cAMP to regulate IL-8
production in other cell types are limited [49, 50], and have mainly
involved the use of CT, which we suggest may exert its effects on
IL-8 production by cAMP-independent means. However, cAMP
has been demonstrated to suppress TNFc and interferon-y in-
duced generation of the chemokine, monocyte-chemoattractant
protein 1 (MCP-i) in mouse mesangial cells [14]. These data
suggest that, although the chemokines IL-8 and MCP-I are
structurally closely related, the signaling pathways engaged to
induce the expression of these chemokines in mesangial cells are
dependent on both the target cell type and the stimulus employed.
In vivo, prostaglandins are one of the main mediators known to
exert modulatory effects on inflammatory events via activation of
the cAMP pathway. Increased PGE2 synthesis in response to
IL-la in cultured MC has been shown previously [27]. We have
extended these findings by demonstrating that inhibition of IL-i
induced PGE2 generation with indomethacin leads to a significant
inhibition of IL-6 generation, but is without effect on the IL-8
production. This suggests that endogenous PGE2 production in
IL-i stimulated MC operates via a positive feedback loop to
up-regulate IL-6 generation, probably through the elevation of
intracellular cAMP. This hypothesis is supported by the lack of
effect of indomethacin on IL-i induced IL-8 generation, further
supporting the data that IL-8 production is not modulated by
cAMP-elevating agents such as PGE2.
Renewed interest in the use of cAMP-elevating compounds as
a therapeutic approach to certain inflammatory disorders has
arisen from studies demonstrating the ability of cAMP to down-
regulate TNFa production in endotoxin-stimulated mononuclear
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cells [15j and IL-6 production in IL-i-stimulated lung fibroblasts
[13]. The results of the present study suggest such a strategy may
not prove to be beneficial in the treatment of mesangioprolifera-
tive glomerulonephritis, in which dysregulated IL-6 production
[51] and IL-S expression have been implicated [2], due to the clear
potentiating effects of cAMP on IL-i-stimulated IL-6 production
and the lack of effect on IL-8 production in cultured human MC.
However, further studies would need to be performed on prolif-
erating cells, in the presence of other growth factors, to address
the clinical relevance of these observations more fully and the net
effect of cAMP on the cytokine network determined.
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